ArticleInternational journal of nanomedicine2026
Development of Curcumin-Loaded Hybrid Lipid-Polymeric Nanoparticles for Hypoxia-Related Applications.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hypoxic and ischemia-associated tissues are often characterized by acidic microenvironments, highlighting the need for drug delivery systems that enable enhanced drug release under acidic conditions. Curcumin (CUR) has antioxidant and cytoprotective properties, but its therapeutic application is limited by poor aqueous solubility and low bioavailability. This study aimed to optimize hybrid lipid-polymeric nanoparticles (HLPNs) as a CUR delivery platform and evaluate their physicochemical properties, colloidal stability, CUR release at pH 7.4 and pH 5.5, and cellular effects under normoxic and hypoxia-mimetic conditions. Methods: In this study, hybrid lipid-polymeric nanoparticles (HLPNs) were optimized as a curcumin (CUR) delivery platform by varying the lipid-to-polymer ratio (DSPE-PEG/cholesterol: PLGA). Particle size, polydispersity index, and zeta potential were determined by dynamic light scattering (DLS) and laser Doppler electrophoresis. The formulations were further characterized in terms of colloidal stability, encapsulation efficiency, morphology, and in vitro CUR release at pH 7.4 and pH 5.5. The effect on cell viability of CUR-loaded HLPNs and free CUR was evaluated in human foreskin fibroblasts (HF) using the MTT assay under normoxic and CoCl Results: Among the tested formulations, HLPNs with lipid-to-polymer ratios of 1:2 and 1:3 showed the most favourable physicochemical profile, with initial particle sizes of ~127 and ~144 nm, respectively, low polydispersity index (~0.12), and negative zeta potentials around -42 mV. After CUR loading, particle size increased to 160 nm for HLPN-CUR 1:2 and 173 nm for HLPN-CUR 1:3. In contrast, encapsulation efficiency reached 38.6% and 40.0%, respectively. Both formulations exhibited pH-dependent CUR release, with minimal release during the first 6 h (<2.0%) and markedly higher cumulative release at pH 5.5 than at pH 7.4 after 72 h. In HF, both CUR-loaded formulations reduced cell viability in a concentration-dependent manner. Free CUR was generally better tolerated than the nanoparticle-loaded formulations. HLPN-CUR 1:3 produced a higher MTT signal under hypoxia-mimetic conditions than under normoxia at 10 µM. However, higher concentrations were associated with marked morphological changes, including cell rounding, aggregation, and reduced cell density. Conclusion: Among the tested formulations, HLPN-CUR 1:3 demonstrated suitable physicochemical properties, colloidal stability, CUR encapsulation, and enhanced CUR release under acidic conditions at later time points. However, the concentration-dependent effects on cell viability and morphology indicate that further studies are needed to confirm its biological activity and potential relevance for hypoxia-related applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.